Cometriq Now Available for Metastatic Medullary Thyroid Cancer

COMETRIQ (cabozantinib) 60mg, 100mg, 140mg daily dose capsule blister cards by Exelixis
COMETRIQ (cabozantinib) 60mg, 100mg, 140mg daily dose capsule blister cards by Exelixis

Exelixis, Inc. announced that Cometriq (cabozantinib) capsules are now available for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).

Cometriq is an inhibitor of multiple receptor tyrosine kinases (including RET, MET, VEGFR2) involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment.

Exelixis has implemented a reimbursement and support program called Exelixis Access Services for co-pay assistance in patients that meet certain financial criteria. This program also offers reimbursement support regarding prior authorization, benefits investigations, and appeals.

Cometriq is being distributed exclusively through Diplomat Specialty Pharmacy. Cometriq is available in 20mg and 80mg strength capsules in 140mg, 100mg, and 60mg daily-dose cartons.

For more information call (855) 253-3273 or visit www.cometriq.com